GT201000093A - Productos quimioterapéuticos cristalinos - Google Patents
Productos quimioterapéuticos cristalinosInfo
- Publication number
- GT201000093A GT201000093A GT201000093A GT201000093A GT201000093A GT 201000093 A GT201000093 A GT 201000093A GT 201000093 A GT201000093 A GT 201000093A GT 201000093 A GT201000093 A GT 201000093A GT 201000093 A GT201000093 A GT 201000093A
- Authority
- GT
- Guatemala
- Prior art keywords
- crystal
- chemotherapeutic products
- chemotherapeutic
- products
- indazol
- Prior art date
Links
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A LA FORMA CRISTALINA 1 DE ETANOLATO DE N-[4-(3-AMINO-1H-INDAZOL-4-IL)FENIL]-N-(2-FLUORO-5-METILFENIL)UREA 1/4, FORMAS DE ELABORARLA, FORMULACIONES QUE LA COMPRENDEN Y ELABORADAS CON LA MISMA Y MÉTODOS QUE LA UTILIZAN PARA EL TRATAMIENTO DE PACIENTES ENFERMOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98131007P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201000093A true GT201000093A (es) | 2012-03-12 |
Family
ID=40174825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201000093A GT201000093A (es) | 2007-10-19 | 2010-04-14 | Productos quimioterapéuticos cristalinos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7994208B2 (es) |
| EP (1) | EP2195300B1 (es) |
| JP (2) | JP5878689B2 (es) |
| KR (1) | KR20100085986A (es) |
| CN (1) | CN101827821B (es) |
| AR (1) | AR068918A1 (es) |
| AU (1) | AU2008312528A1 (es) |
| BR (1) | BRPI0818067A2 (es) |
| CA (1) | CA2699302C (es) |
| CL (1) | CL2008003091A1 (es) |
| CO (1) | CO6280482A2 (es) |
| CR (1) | CR11387A (es) |
| DO (1) | DOP2010000113A (es) |
| EC (1) | ECSP10010182A (es) |
| ES (1) | ES2547878T3 (es) |
| GT (1) | GT201000093A (es) |
| MX (1) | MX2010004288A (es) |
| PA (1) | PA8800301A1 (es) |
| PE (1) | PE20091075A1 (es) |
| RU (1) | RU2010119927A (es) |
| TW (1) | TW200932728A (es) |
| UA (1) | UA99747C2 (es) |
| UY (1) | UY31408A1 (es) |
| WO (1) | WO2009052225A1 (es) |
| ZA (1) | ZA201002180B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994208B2 (en) * | 2007-10-19 | 2011-08-09 | Abbott Laboratories | Crystalline chemotherapeutic |
| US20140212355A1 (en) * | 2013-01-28 | 2014-07-31 | Abbott Cardiovascular Systems Inc. | Trans-arterial drug delivery |
| JP7346916B2 (ja) * | 2019-06-04 | 2023-09-20 | 京セラドキュメントソリューションズ株式会社 | 緩衝構造体およびそれを備えた包装材 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| PT1638941E (pt) | 2003-05-22 | 2010-08-24 | Abbott Lab | Inibidores de quinases de indazole, benzisoxazole e benzisotiazole |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| EP1925676A4 (en) * | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| CN101346128B (zh) | 2005-10-25 | 2013-10-02 | 雅培制药有限公司 | 包含低水溶解度药物的配方及其使用方法 |
| WO2007076358A1 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| CA2667720A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg. | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| US7994208B2 (en) * | 2007-10-19 | 2011-08-09 | Abbott Laboratories | Crystalline chemotherapeutic |
-
2008
- 2008-10-15 US US12/251,949 patent/US7994208B2/en not_active Expired - Fee Related
- 2008-10-16 WO PCT/US2008/080060 patent/WO2009052225A1/en active Application Filing
- 2008-10-16 RU RU2010119927/04A patent/RU2010119927A/ru not_active Application Discontinuation
- 2008-10-16 MX MX2010004288A patent/MX2010004288A/es active IP Right Grant
- 2008-10-16 JP JP2010530089A patent/JP5878689B2/ja not_active Expired - Fee Related
- 2008-10-16 EP EP08840138.5A patent/EP2195300B1/en active Active
- 2008-10-16 ES ES08840138.5T patent/ES2547878T3/es active Active
- 2008-10-16 BR BRPI0818067 patent/BRPI0818067A2/pt not_active IP Right Cessation
- 2008-10-16 KR KR1020107010989A patent/KR20100085986A/ko not_active Application Discontinuation
- 2008-10-16 AU AU2008312528A patent/AU2008312528A1/en not_active Abandoned
- 2008-10-16 UA UAA201006034A patent/UA99747C2/ru unknown
- 2008-10-16 CN CN200880111903XA patent/CN101827821B/zh not_active Expired - Fee Related
- 2008-10-16 CA CA2699302A patent/CA2699302C/en not_active Expired - Fee Related
- 2008-10-17 PA PA20088800301A patent/PA8800301A1/es unknown
- 2008-10-17 TW TW097140031A patent/TW200932728A/zh unknown
- 2008-10-17 AR ARP080104544A patent/AR068918A1/es not_active Application Discontinuation
- 2008-10-17 UY UY31408A patent/UY31408A1/es not_active Application Discontinuation
- 2008-10-17 PE PE2008001782A patent/PE20091075A1/es not_active Application Discontinuation
- 2008-10-17 CL CL2008003091A patent/CL2008003091A1/es unknown
-
2010
- 2010-03-26 ZA ZA2010/02180A patent/ZA201002180B/en unknown
- 2010-04-14 GT GT201000093A patent/GT201000093A/es unknown
- 2010-04-16 DO DO2010000113A patent/DOP2010000113A/es unknown
- 2010-04-23 CR CR11387A patent/CR11387A/es not_active Application Discontinuation
- 2010-04-27 CO CO10049263A patent/CO6280482A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010182A patent/ECSP10010182A/es unknown
-
2014
- 2014-09-29 JP JP2014198628A patent/JP2015042650A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009052225A1 (en) | 2009-04-23 |
| US7994208B2 (en) | 2011-08-09 |
| CN101827821B (zh) | 2012-09-05 |
| EP2195300B1 (en) | 2015-06-24 |
| CN101827821A (zh) | 2010-09-08 |
| ZA201002180B (en) | 2011-10-26 |
| ES2547878T3 (es) | 2015-10-09 |
| KR20100085986A (ko) | 2010-07-29 |
| JP5878689B2 (ja) | 2016-03-08 |
| US20090105326A1 (en) | 2009-04-23 |
| CL2008003091A1 (es) | 2009-09-04 |
| UA99747C2 (en) | 2012-09-25 |
| PE20091075A1 (es) | 2009-08-27 |
| EP2195300A1 (en) | 2010-06-16 |
| MX2010004288A (es) | 2010-04-30 |
| CR11387A (es) | 2010-08-18 |
| JP2015042650A (ja) | 2015-03-05 |
| TW200932728A (en) | 2009-08-01 |
| UY31408A1 (es) | 2009-05-29 |
| AU2008312528A1 (en) | 2009-04-23 |
| BRPI0818067A2 (pt) | 2015-03-31 |
| CA2699302A1 (en) | 2009-04-23 |
| DOP2010000113A (es) | 2010-07-31 |
| AR068918A1 (es) | 2009-12-16 |
| CA2699302C (en) | 2016-06-21 |
| ECSP10010182A (es) | 2010-06-29 |
| RU2010119927A (ru) | 2011-11-27 |
| JP2011500704A (ja) | 2011-01-06 |
| CO6280482A2 (es) | 2011-05-20 |
| PA8800301A1 (es) | 2009-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| EA201300200A1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
| CU23515A3 (es) | Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen | |
| UY33547A (es) | COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL | |
| UY32535A (es) | Métodos e intermediarios para la preparación de agentes farmacéuticos | |
| GT200600086A (es) | Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| CL2015002346A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
| AR079945A1 (es) | Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3) | |
| MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| CR11368A (es) | Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida | |
| AR073591A1 (es) | Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida,composiciones farmaceuticas que las contienen,utiles para el tratamiento de carcinomas. | |
| GT201000093A (es) | Productos quimioterapéuticos cristalinos | |
| UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
| ECSP10010176A (es) | Productos quimioterapéuticos cristalinos | |
| ECSP10010175A (es) | Productos quimioterapéuticos cristalinos | |
| ATE481395T1 (de) | Cyclohexylderivate | |
| DOP2010000116A (es) | Productos quimioterapeuticos cristalinos | |
| GT200600141A (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares | |
| CL2007000836A1 (es) | Uso de compuestos derivados de estrobilurina y/o sus sales fisiologicamente toleradas para preparar un medicamento para el tratamiento y/o prevencion de trastornos del metabolismo del hierro. | |
| UY31407A1 (es) | "productos quimioterapéuticos cristalinos" | |
| ECSP10010177A (es) | Productos quimioterapéuticos cristalinos | |
| CU20070232A7 (es) | Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares | |
| CU20100265A7 (es) | Compuestos químicos 251 |